Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Control, Exploratory Trial to Compare Anlotinib Plus Chemotherapy Versus Chemotherapy as Second-line Treatment in Subjects With Advanced Non-small Cell Lung Cancer

NCT03589950 is registered in ClinicalTrials.gov with The First People's Hospital of Lianyungang as lead sponsor.

NCT NCT03589950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03589950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Control, Exploratory Trial to Compare Anlotinib Plus Chemotherapy Versus Chemotherapy as Second-line Treatment in Subjects With Advanced Non-small Cell Lung Cancer
Lead sponsor
The First People's Hospital of Lianyungang
Phase
Phase 2
Overall status
Unknown status
Start date
August 1, 2018
Completion date
August 1, 2021
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anlotinib, docetaxel, lung neoplasms, pemetrexed, s-1